CeMines

CeMines was a biotechnology company dedicated to the development of molecular diagnostic tests for the early detection of various cancers. The company utilized its proprietary 'Molecular Fingerprinting' platform to identify specific patterns of autoantibodies in blood samples, which served as biomarkers for malignancy. Their primary focus was on providing non-invasive, cost-effective screening tools for lung, breast, and prostate cancers. By combining proteomics with advanced bioinformatics, CeMines sought to improve patient outcomes through earlier intervention. Although the company successfully commercialized a lung cancer diagnostic, it is no longer active in the market.